Welcome to our dedicated page for Pro-Dex Colo SEC filings (Ticker: PDEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the story behind Pro-Dex’s precision surgical drivers and motion-control boards? Most investors start by scanning a single Form 8-K, then realise the real details hide across hundreds of pages of 10-K, 10-Q and proxy statements. This page brings every Pro-Dex SEC filing into one place and, more importantly, explains what each document means for revenue tied to a handful of medical-device OEMs, FDA compliance costs, and new driver technology in development.
Use Stock Titan’s AI summaries to turn the dense language of a Pro-Dex annual report 10-K simplified into clear bullet points, or let our engine flag sudden shifts in backlog within the latest Pro-Dex quarterly earnings report 10-Q filing. Need immediate alerts? We stream Pro-Dex Form 4 insider transactions real-time so you can track director purchases the moment they hit EDGAR. Curious about pay packages? The Pro-Dex proxy statement executive compensation section is distilled so you can compare cash bonuses to patent milestones in seconds.
Common tasks become effortless: monitor Pro-Dex insider trading Form 4 transactions before material announcements, dissect segment margins with our Pro-Dex earnings report filing analysis, and see every Pro-Dex 8-K material events explained without opening a single PDF. Whether you’re underwriting credit, valuing the stock, or simply understanding Pro-Dex SEC documents with AI, this hub delivers all filings, real-time updates, and plain-English insights—so you spend time on decisions, not document mining.
Aureus Greenway Holdings Inc. (AGH) filed an 8-K announcing a $26 million private placement that closed on 25 Jul 2025. Investors purchased 29.89 million shares (or pre-funded warrants) bundled with an equal number of five-year common warrants A (exercise $1.00) and warrants B (exercise $1.25) at an all-in price of $0.87 per unit. Placement agents Revere Securities and Dominari Securities earned an 8 % cash fee ($2.08 million), expense reimbursement of $0.15 million, and 2.39 million five-year warrants exercisable at $1.00.
The deal is exempt from registration under Rule 506(b) and Section 4(a)(2); however, AGH committed to file a resale registration statement within 10 days and seek effectiveness within 45 (75 if fully reviewed) days. A 180-day lock-up restricts additional equity issuance.
Concurrently, certain existing shareholders sold 10 million Series A preferred shares at $0.01 and 4 million common shares at $0.975 to new buyers for a combined $4 million under a separate stock purchase agreement. All transactions include customary reps, warranties, indemnities and cashless exercise provisions capped at 4.99 % (optionally 9.99 %) ownership.
Net proceeds (after fees) are earmarked for working-capital needs. The placement could increase AGH’s fully diluted share count by more than 60 million shares, creating material dilution but materially strengthening liquidity.